Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.

Ruggiero AngeloG FabbrociniEleonora CinelliS S Ocampo GarzaElisa Camela Matteo Megna

Published in: Clinical and experimental dermatology (2021)

The three anti-IL-23 therapies assessed are promising, safe and effective options in elderly patients, and there was no significant difference between them. However, more data are needed to confirm our results and to understand their role in the management of this group of patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
healthcare
primary care
prognostic factors
peritoneal dialysis
electronic health record
machine learning
big data